Bristol Myers Squibb Camzyos Wins Fda Approval For Pediatric Ohcm

A label expansion for Camzyos (mavacamten) now places Bristol Myers Squibb's cardiac myosin inhibitor inside pediatric formularies for the first time, carrying with it the full weight of the existing Camzyos REMS and its boxed warning for heart failure risk, operational realities that dispensing sites and specialty pharmacy partners will need to address immediately.

The FDA approved mavacamten on 30 September 2026 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in patients aged 12–18 years weighing at least 30 kg, extending a label first granted for adults in 2022. The approval carries orphan drug designation, reflecting the limited patient population and the regulatory incentives that accompany it, including market exclusivity provisions relevant to any manufacturer evaluating a competing program in this space.

Efficacy data supporting the pediatric indication came from SCOUT-HCM (NCT-06253221), a phase 3, randomized, double-blind, placebo-controlled multicenter study enrolling 44 patients over 28 weeks. The primary endpoint, change from baseline in Valsalva left ventricular outflow tract (LVOT) gradient, showed a statistically significant reduction versus placebo. Because the adult dataset already linked LVOT gradient reduction to improved functional capacity and symptom burden, the agency accepted extrapolation of those clinical outcomes to the pediatric cohort, a regulatory pathway QA and regulatory affairs teams should note when structuring future pediatric bridging strategies.

The REMS program remains the central compliance obligation. Sites dispensing Camzyos must maintain enrollment in the restricted distribution framework, conduct required echocardiographic monitoring, and document prescriber certification, requirements that do not change with the label expansion but now apply across a broader, younger patient population. Dizziness and syncope were reported in more than 5% of pediatric trial participants receiving mavacamten versus placebo, reinforcing the monitoring cadence already embedded in REMS protocols.

For manufacturers and CDMOs supplying mavacamten or evaluating the cardiac myosin inhibitor class, the orphan designation and pediatric exclusivity provisions will factor into lifecycle planning and any abbreviated new drug application (ANDA) timelines in this indication.

The measurable checkpoint ahead is REMS audit performance across newly enrolled pediatric dispensing sites, where echocardiographic compliance rates will serve as the earliest indicator of whether the program scales without deviation.

Source: U.S. Food and Drug Administration, FDA Drug Approvals RSS Feed, 30 September 2026.